Anticoagulant rodenticide novel candidates predicted by evolutionary docking

02 June 2023, Version 1
This content is a preprint and has not undergone peer review at the time of posting.


The evolutionary docking generation of high numbers of potentially novel anticoagulant rodenticides is described here. In particular, made-on-demand libraries were generated by randomly introducing small molecular variations into alphafold-modeled brodifacoum-rat VKORC1 binding-cavity. For evolution of the brodifacoum parent, criteria were mainly optimized to fit-dock the brodifacoum cavity. Libraries of specific brodifacoum-children were selected by pooling those predicting higher affinities (lower binding-scores) at various molecular weights. The selected brodifacoum-children were filtered for known toxicities, desirable high affinity to recently identified spanish resistance rat mutants and undesirable high affinities to human VKORC1. The flexible threshold-adjustable new chemotype brodifacoum-children libraries constitute an step forward towards further in silico fine-tuning to computationally reduce other possible unspecific off-target ecological impacts


evolutionary libraries

Supplementary materials

Library C containing 150 children with filters in Data Warrior dwar
The Table shows a prove-of-concept example of the evolutionary docking results described in the paper methodology. The docking-score thresholds of < -100 were applied to retain higher-affinities to rat wild-type and spanish mutants and the same threshold was applied to skip higher-affinities to human VKORC1. Any other thresholds can be applied using the filters at the right of the table. The dwar filecan be opened at Data Warrior free access


Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.